Drug Discovery

Can AI-Powered Digital Twins Revolutionize ALS Clinical Trials?
Research & Development Can AI-Powered Digital Twins Revolutionize ALS Clinical Trials?

The rapid advancement of artificial intelligence (AI) has made significant strides in many sectors, and the realm of healthcare is no exception. Among the promising innovations is the use of AI-powered digital twins in clinical trials, particularly those targeting complex diseases like Amyotrophic

Can Reverse Genetics Advance Vaccines for African Swine Fever?
Biotech & Bioprocessing Can Reverse Genetics Advance Vaccines for African Swine Fever?

African swine fever (ASF) is a highly contagious and deadly viral disease affecting both domesticated and wild pigs. With its widespread prevalence in areas such as Africa, Europe, Asia, and the Caribbean, this disease has significant economic implications. Recent estimates state that if ASF were

How Can Generative AI Revolutionize Clinical Trials?
Research & Development How Can Generative AI Revolutionize Clinical Trials?

Clinical trials have long been a cornerstone of medical research, essential for the development and approval of new drugs and treatments. However, they are often plagued by high costs, time constraints, and the complexities associated with patient recruitment. In recent years, the transformative

Harnessing Real-World Evidence to Streamline FDA Drug Approvals
Management & Regulatory Harnessing Real-World Evidence to Streamline FDA Drug Approvals

The article delves into the intriguing potential of real-world evidence (RWE) to revolutionize the U.S. Food and Drug Administration’s (FDA) approval process for new drugs. By relying more on real-world data (RWD), regulatory decisions could become quicker, more economical, and maintain the current

How Will Roche's Billion-Dollar OBT Partnership Transform Cancer Therapy?
Biotech & Bioprocessing How Will Roche's Billion-Dollar OBT Partnership Transform Cancer Therapy?

Roche has recently entered into a groundbreaking multi-year collaboration with Oxford BioTherapeutics (OBT), valued at over a billion dollars, to spearhead the development of novel antibody-based cancer treatments. This significant partnership focuses on the creation of innovative therapies such as

Can Schrödinger’s AI Shift Transform Drug Discovery and Boost Growth?
Research & Development Can Schrödinger’s AI Shift Transform Drug Discovery and Boost Growth?

Schrödinger, a well-established player in the computational chemistry and drug discovery space, has recently made headlines by embracing artificial intelligence (AI). The company’s CEO, Ramy Farid, officially announced this strategic pivot during the presentation of the company's year-end re

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later